Incretin drugs, which may be helpful both in compensating for metabolic disorders caused by antipsychotic treatment and in the causal treatment of schizophrenia, seem to be a new therapeutic option, offering hope for patients with schizophrenia. The gene discussed is GCG; the disease is metabolic disease.